Chugai – Positive Data for Emicizumab from HAVEN 2
After Alecensa impressed in Phase III trials earlier this week, Chugai (4519 JP) had the added pleasure of seeing emicizumab do well in the second...
231 Views
Chugai Pharmaceutical: Update Ahead of Summer Data Releases
The excitement at Chugai Pharmaceutical (4519 JP) is palpable for all to see, and you quickly get the impression at any meeting that the company is...
149 Views
Chugai Pharmaceutical-Exceptionally Productive In-House R&D Driving Strong Growth
We publish an in-depth analysis of Chugai Pharmaceutical arriving at a DCF derived fair value of ¥ 4,200. Chugai’s strategic alliance with its...
203 Views
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
522 Views
Cybercriminals and Activists Scale up Their Attacks – Who's at Risk and Why?
Distributed denial of service (DDoS) attacks have significantly increased in size, carried out by threat actors exploiting internet of things (IoT)...
313 Views